Zhao Shigang, Cheng Yan, Liao Yali, Zhang Zhelin, Yin Xuhua, Shi Shujun
Department of Neurology, Affiliated Hospital, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China (mainland).
Department of Neurology, Tianjin Medical University General Hospital, Tianjin, China (mainland).
Med Sci Monit. 2016 Mar 28;22:1005-12. doi: 10.12659/msm.897947.
This study aimed to analyze the risk factors and treatment efficacy of neurobrucellosis.
MATERIAL/METHODS: A cross-sectional epidemiologic survey was carried out in 557 patients with brucellosis by specially trained neurologic clinicians. Sixty-six patients with neurobrucellosis were treated with doxycycline, rifampicin, and ceftriaxone sodium as standard medication and evaluated for efficacy on a regular basis.
(1) Symptoms improved in most patients after 6 weeks of treatment, which demonstrated a favorable efficacy. (2) Cross-sectional epidemiologic survey suggested that sex, nationality, and regional distribution were not related to nervous system damage in patients with brucellosis (P>0.05), whereas age and duration of disease were related factors. Increased age as well as a prolonged duration of disease were risk factors for nervous system damage in patients with brucellosis (P<0.05).
(1) Doxycycline, rifampicin, and third-generation cephalosporins should be considered both standard and first-choice medications for neurobrucellosis. Treatment should last for at least 6 weeks. Standardized, sufficient, and combined medication is recommended for better efficacy and prognosis. (2) Age and duration of disease are risk factors for neurobrucellosis, whereas sex, nationality, and regional distribution are not. Older patients with a prolonged duration of disease are more likely to develop neurobrucellosis.
本研究旨在分析神经型布鲁氏菌病的危险因素及治疗效果。
材料/方法：由经过专门培训的神经科临床医生对557例布鲁氏菌病患者进行横断面流行病学调查。66例神经型布鲁氏菌病患者采用多西环素、利福平及头孢曲松钠作为标准用药进行治疗，并定期评估疗效。
（1）多数患者治疗6周后症状改善，显示出良好疗效。（2）横断面流行病学调查表明，布鲁氏菌病患者的性别、国籍及地区分布与神经系统损害无关（P>0.05），而年龄和病程是相关因素。年龄增加及病程延长是布鲁氏菌病患者神经系统损害的危险因素（P<0.05）。
（1）多西环素、利福平及第三代头孢菌素应被视为神经型布鲁氏菌病的标准及首选用药。治疗应持续至少6周。建议采用标准化、足量及联合用药以获得更好疗效及预后。（2）年龄和病程是神经型布鲁氏菌病的危险因素，而性别、国籍及地区分布不是。病程延长的老年患者更易发生神经型布鲁氏菌病。
